Publications by authors named "Yves Michiels"

Patients with multiple sclerosis (MS) are treated with drugs that may impact immune responses to SARS-CoV-2 vaccination. Evaluation of "prime-boost" (heterologous) vaccination regimens including a first administration of a viral vector-based vaccine and a second one of an mRNA-based vaccine in such patients has not yet been completed. Here, we present the anti-spike protein S humoral response, including the neutralizing antibody response, in a 54-year-old MS patient who had been treated with teriflunomide for the past 2 years and who received a heterologous ChAdOx1 nCoV-19/ BNT162b2 vaccination regimen.

View Article and Find Full Text PDF
Article Synopsis
  • * This case study focuses on a 78-year-old RA patient who received the mRNA-1273 vaccine shortly after starting low-dose therapy with methotrexate and adalimumab.
  • * The findings suggest that even low doses of this combination therapy can lead to a weaker immune response to the vaccine in older adults.
View Article and Find Full Text PDF

Objective: A real-world, randomized study assessing the impact of a new, personalized, pharmacist-led text messaging service for managing type 2 diabetes (T2D).

Methods: Messages were tailored to patient's needs based on their disease management habits, propensity for reactance, and physical activity levels at baseline. Treatment adherence (assed using the Morisky Medication Adherence Scale, MMAS-8, questionnaire), clinical factors (body mass index and physical activity) and biological markers for T2D were compared between patients who received a text message daily for 3 months in addition to standard care (SMS group) and those who received standard care alone (control group).

View Article and Find Full Text PDF

Introduction: Low-quality communication between patients and care providers and limited patient knowledge of the disease and the therapy are important factors associated with poor glycemic control in patients with type 2 diabetes. We conducted a multicenter study to determine whether structured and tailored information delivered by pharmacists to type 2 diabetic patients could improve patient treatment adherence, hemoglobin A1c (HbA1c) levels and knowledge about diabetes.

Methods: One hundred seventy-four pharmacies were randomized to deliver an educational program on diet, drug treatment, disease and complications during three 30-min interviews over a 6-month period, or to provide no intervention, to type 2 diabetic patients treated with oral antidiabetic agents.

View Article and Find Full Text PDF
Article Synopsis
  • A 52-year-old Caucasian patient with relapsing-remitting multiple sclerosis developed an unclassified skin cancer, a rare occurrence among patients treated with fingolimod.
  • This patient had no history of melanoma, minimal skin lesions, and limited sun exposure, making her case unique compared to typical melanoma cases reported in other studies.
  • The overall incidence of skin cancer in multiple sclerosis patients is low, but recent cases emphasize the need for enhanced dermatological monitoring for these individuals.
View Article and Find Full Text PDF